Showing results (151-160 of 218) with videos related to
Sort By:
Pageof 22
Nature Cancer|August 29, 2022
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancerRami S Vanguri, Jia Luo, Andrew T Aukerman, et al.Science (New York, N.Y.)|March 14, 2015
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerNaiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, et al.British Journal of Cancer|December 29, 2021
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancersYonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Treatment Outcomes of Immune-Related Cutaneous Adverse EventsGregory S Phillips, Jennifer Wu, Matthew D Hellmann, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell AnalysisIla Datar, Miguel F Sanmamed, Jun Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsKyung Hae Jung, Patricia LoRusso, Howard Burris, et al.Nature Medicine|July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.Nature|June 18, 2019
TOX is a critical regulator of tumour-specific T cell differentiationAndrew C Scott, Friederike Dündar, Paul Zumbo, et al.European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.Pageof 22